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Abstract Expression of Rap1 blocks epithelial growth factor-
induced extracellular signal-regulated kinases (ERKs) activation.
However, recent studies demonstrated that Rap1 mediates ERKs
activation induced by nerve growth factor. The anti-oncogenic
effect of Rap1 has been reported but its mechanism remains
unclear. To evaluate the correlation between the anti-transform-
ing effect and the activation of ERKs, we transfected rap1 cDNA
into Hep3B cells and selected stable transfectants. The Rap1
transfectants completely lost their intrinsic tumorigenicity in
Balb/c nude mice. Both insulin and 12-O-tetradecanoyl phorbol-
13-acetate (TPA)-stimulated ERK activations were also blocked.
Our findings suggest that Rap1-suppressed tumorigenicity is
concomitant with ERKs inhibition.
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1. Introduction
Rap1 is a small GTPase that was identi¢ed in a screen for
Ras homologous proteins [1] and independently as a suppres-
sor of v-Ki-ras transformation [2]. It has an e¡ector domain
identical to the e¡ector domain of Ras. The active form of
Rap1 was found to bind to most Ras e¡ectors, e.g. Raf-1 and
B-raf, the Ral guanine nucleotide exchange factors (RalGEFs)
RalGDS, Rgl and Rlf [3^5]. This has prompted the specula-
tion that Rap1 may antagonize Ras functions by sequestering
Ras e¡ectors in a non-productive complex. For instance, over-
expression of active Rap1 inhibits Ras-induced germinal
vesicle breakdown in Xenopus oocytes, and in mammalian
cells antagonizes the Ras-dependent activation of extracellular
signal-regulated kinase (ERK) pathway [6,7]. Several studies
have demonstrated that there is substantial similarity in the
upstream signaling mechanism that regulates both Ras and
Rap1 activation. Ras-GTP binding is stimulated by Ras-
GEF SOS [8]. The carboxyl-terminal domain of SOS contains
a proline-rich region that directs its association with the SH3
domain of the small adapter protein, GRB2 [9,10]. In analogy,
the formation of GTP-bound Rap1 results from the speci¢c
interaction with Rap1 GEF C3G [11,12]. The proline-rich
regions of C3G are responsible for association with the central
SH3 domain of the adapter protein, CrKII [13]. Identi¢cation
of these associated proteins has led to the hypothesis that
Rap1 proteins have other physiological roles in addition to
Ras-antagonizing e¡ects. In PC12 cells, it was suggested that
cAMP activates Rap1, and this activation induces association
of Rap1 and B-Raf, leading to the activation of ERK [14].
Furthermore, Rap1 mediates sustained ERK activation in-
duced by nerve growth factor through a Ras-independent
pathway in these cells [15]. Zwartkruis et al. have shown
that Rap1 is also rapidly activated following stimulation of
a large variety of growth factor receptors, including receptor
tyrosine kinase for platelet-derived growth factor and epithe-
lial growth factor (EGF), but not insulin. 12-O-Tetradecanoyl
phorbol-13-acetate (TPA), which mimics diacylglycerol, also
induces Rap1 activation. In their studies, activation of endog-
enous Rap1 failed to a¡ect Ras-dependent ERK activation
[16].
Insulin induces a variety of physiological responses includ-
ing stimulation of cell proliferation and modulation of speci¢c
gene expression in its target cells [17,18]. It elicits these e¡ects
by binding to speci¢c cell surface receptor, which activates the
protein tyrosine kinase intrinsic to the L-subunit of the recep-
tor [19]. Two immediate substrates of insulin receptor, insulin
receptor substrate 1 and 2 (IRS-1 and IRS-2) have been iden-
ti¢ed [20,21]. These IRS proteins can be phosphorylated by
activated insulin receptor and then act as docking proteins to
bind the p85 regulatory subunit of phosphatidylinositol-3 ki-
nase and growth factor receptor binding protein 2 (GRB2)
through their Src homology-2 domains [22,23]. The GRB2
then physically interacts with Ras-GEF, SOS. Binding of
GRB2 and SOS to IRS-1 provides a functional complex nec-
essary for Ras activation. Once in the active GTP-bound
state, Ras directly associates and activates Raf-1 kinase. In
turn, activated Raf-1 phosphorylates mitogen-activated/extra-
cellular signal-regulated kinase kinase (MEK), which is an
immediate upstream activator of ERKs [24,25]. The phorbol
ester, TPA, has been shown to mimic insulin-like e¡ects on
glucose transport, glucose oxidation and lipogenesis in adipo-
cytes and some other cell types [26]. It has been well docu-
mented that insulin and TPA activate Ras/Raf-1/MEK/ERKs
in many cells. With respect to Rap1, these two agents seem to
have di¡erent e¡ects. In Rat-1 cells, TPA activates endoge-
nous Rap1 and this activation fails to a¡ect Ras-dependent
ERK activation, while insulin has no e¡ect on Rap1 activity
[16]. In Chinese hamster ovary (CHO) cells, insulin induces a
time-dependent uncoupling of Raf-1 from Rap1 with a con-
comitant association of Raf-1 with Ras, which then activates
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the downstream Raf-1/MEK/ERK cascade [27]. We have ob-
served that TPA mimics insulin e¡ects in the stimulation of
proto-oncogene expression, cell proliferation and the suppres-
sion of hepatitis B surface antigen expression in human hep-
atoma Hep3B cells [28]. To verify the e¡ects of insulin and
TPA upon Rap1 activity, we transfected wild-type Rap1
cDNA into Hep3B cells and selected stable transfectants.
This approach allowed us to study the role of Rap1 upon
ERK activation while stimulating with insulin or TPA,
through the ampli¢cation of Rap1 signal by expressing
Rap1 in Hep3B cells.
It has been intensively discussed whether rap genes are anti-
oncogenes [29]. Jelinek and Hassel have shown that rap1 gene
induced the reversion of polyomavirus middle T antigen-
transformed Rat-2 cells [30]. Most evidences supported the
conclusion that overexpression of rap1 genes does induce re-
version of malignant phenotypes in certain tumor cell lines
[31,32]. However, an oncogenic e¡ect of Rap1b has been re-
ported in Swiss 3T3 cells, in which Rap1 increases DNA syn-
thesis and cAMP exerts a stimulatory e¡ect on cell growth
[33]. With these rather paradoxical results, it will be interest-
ing to verify the correlation between either the anti-oncogenic
e¡ect and ERKs inactivation or oncogenic e¡ect and ERKs
activation. In this paper, we attempted to verify the e¡ect of
Rap1 upon ERKs activation by insulin or TPA and the cor-
relation between the oncogenic or anti-oncogenic e¡ect of
Rap1 and ERKs activation in Hep3B cells. We found that
expression of Rap1 reduced the saturation density of Hep3B
cells and suppressed their intrinsic tumorigenicity. Further-
more, the activation of ERKs by insulin or TPA was blocked
in Rap1 transfectants. Taken together, in Hep3B cells, Rap1
plays a negative role on ERKs activation by either insulin or
TPA and this ERKs inactivation is concomitant with the sup-
pression of tumorigenesis.
2. Materials and methods
2.1. Cell culture
Human hepatoma Hep3B cells were kindly given by Dr. B.
Knowles (Wista Institute, PA, USA). Cells were maintained in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) (Gibco) containing 10%
fetal calf serum (FCS, Gibco) in an atmosphere of 5% CO2, 95% air at
37‡C.
2.2. Calcium-phosphate DNA transfection and G418 selection of Rap1
stable transfectants
Human rap1/krev-1 cDNA was transfected into Hep3B cells using
the calcium-phosphate method as described [34]. The transfected cells
were then selected using 1 mg/ml of G418. After 2 weeks of G418
selection, surviving colonies were isolated.
2.3. Western blot analysis of ERKs or tyrosine phosphorylation pattern
Hep3B cells were seeded at a density of 2U106 cells/100 mm plate
with 10% FCS. After 16 h, the culture medium was changed to serum-
free DMEM for 48 h. The serum-starved cells were then treated with
1039 M or 1037 M insulin for 10 min. The cells were then washed in
ice-cold PBS (pH 7.4) and lysed using lysis bu¡er containing 50 mM
HEPES (pH 7.8), 4 mM EDTA, 2 mM EGTA, 5 Wg/ml leupeptin,
2 mM phenylmethylsulfonyl £uoride, 5 Wg/ml aprotinin and 1% Tri-
ton X-100. Cell lysate was centrifuged at 100 000Ug for 30 min at
4‡C. Supernatant (100 Wg of protein) was resolved by 10% sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and
electrotransferred to nitrocellulose in transfer solution containing
25 mM Tris, 192 mM glycine, 20% methanol. The blot was incubated
overnight in bu¡er containing 25 mM Tris (pH 8.0), 125 mM NaCl,
0.05% Tween 20, 0.1% sodium azide and 3% skim milk. The nitro-
cellulose paper was then probed with anti-ERKs polyclonal antibody
or anti-phosphotyrosine antibodies (PY20, PY69) for 3 h at room
temperature and then washed three times with Tris-bu¡ered saline
(25 mM Tris (pH 8.0), 125 mM NaCl). Mobility shift was detected
using the enhanced chemiluminescence detection system (Amersham).
3. Results
3.1. Expression of Rap1 reduces the saturation density of
Hep3B cells in culture
The 1.8 kb of rap1 cDNA was constructed into a pCD2
vector containing a neomycin resistance gene under the regu-
lation of an SV40 early promoter. After transfection into the
human hepatoma cell line Hep3B, Rap1 stable transfectants
were selected using 1 mg/ml G418. The surviving colonies
were recovered after 2 weeks of selection. Expression of
rap1 gene was con¢rmed by Northern blotting using rap1
cDNA as a probe. Two di¡erent clones (Rap1-3, Rap1-12)
were chosen for following studies according to their di¡erent
expression levels of rap1 mRNA. Another control clone was
also selected, which was transfected with a mock vector con-
taining only a neomycin resistance gene under the regulation
of an SV40 promoter.
We ¢rst investigate whether expression of Rap1 changes the
growth property of Hep3B cells. Hep3B derivatives were cul-
tured in 24-well plates with DMEM containing 10% FCS. As
seen in Fig. 1A, the growth rates of parental cells and Rap1
Fig. 1. Growth properties of Hep3B, Hep3B/Neo, Hep3B/Rap1
cells. The derivatives of Hep3B cells were seeded in 24-well plates
with DMEM containing (A) 10% FCS or (B) 0% FCS. The culture
medium was changed every 2 days. The cell numbers were counted
using hemocytometry every 48 h.
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transfectants were similar for the ¢rst 4 days. After 4 days in
culture, Rap1 transfectants became con£uent and their cell
numbers did not increase until the end of culture, while cell
number of parental Hep3B cells kept increasing until the day
6, then became saturated. The saturation densities of two
Rap1-transfected clones were reduced by 40% comparing to
that of control cells. As Hep3B cells can steadily divide even
in a serum-free culture condition, we also evaluated growth
properties of Hep3B derivatives in a serum-free medium. A
similar phenomenon was found, as shown in Fig. 1B. This
phenomenon is not a non-speci¢c e¡ect because Hep3B/Neo
control cells have the same saturation density as Hep3B pa-
rental cells.
3.2. Expression of Rap1 suppresses the tumorigenicity of
Hep3B cells
As Rap1 reduces the saturation density, we further ob-
served whether Rap1 suppresses the tumorigenicity of
Hep3B cells. Two di¡erent Rap1 transfectants (Rap1-3 and
Rap1-12) and parental Hep3B cells were inoculated into the
upper back of Balb/c nude mice at two cell densities. As seen
in Table 1, parental Hep3B cells induced 100% tumorigenesis,
while two Rap1 clones lost this oncogenic e¡ect.
3.3. Expression of Rap1 inhibits insulin- or TPA-induced ERKs
activation
We then investigated the e¡ect of Rap1 upon ERKs acti-
vation by insulin and TPA. Cells were treated with 1038 M
insulin for 10 min after 48 h serum starvation. As seen in Fig.
2A, 1038 M insulin stimulated the phosphorylation of ERKs,
which induces mobility shifts of ERK-1 and ERK-2 in an
Table 1












Hep3B, Hep3B/Rap1-3 and Hep3B/Rap1-12 cells were subdermally
injected into the upper backs of Balb/c nude mice with di¡erent
doses. The tumor formation was measured at the day 49 after inoc-
ulation.
Fig. 2. ERKs activation induced by (A) insulin or (B) TPA in both
Hep3B and Hep3B/Rap1 cells. Hep3B and Hep3B/Rap1-3 cells were
treated with (A) 1038 M insulin for 10 min or (B) 10 and 50 ng/ml
TPA for 5 min after 48 h serum starvation. Cell extracts were har-
vested and analyzed in 10% SDS^PAGE. The mobility property of
ERKs was detected using anti-ERKs antibody as described in Sec-
tion 2. SF, control cells ; INS, insulin-treated cells.
Fig. 3. Mitogenesis induced by (A) insulin or (B) TPA in Hep3B
and Hep3B/Rap1 cells. The derivatives of Hep3B cells were seeded
in 24-well plates. After 48 h serum starvation, these cells were
treated with various concentrations of (A) insulin or (B) TPA for
another 48 h. Cell numbers were counted using hemocytometry.
Percentage of cell number was determined in the insulin-treated
groups, as compared with the serum-free DMEM groups (SF) which
were considered as 100% in cell number.
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acrylamide gel. However, insulin could not induce a mobility
change in Rap1-expressing cells. Hep3B and Rap1 transfec-
tants were treated with di¡erent concentrations of TPA. As
seen in Fig. 2B, 10 or 50 ng/ml TPA induced the phosphor-
ylation of ERK-1 and ERK-2 proteins after 5 min treatment,
however, this e¡ect was reduced in Rap1A cells.
3.4. Expression of Rap1 also inhibits insulin- and TPA-induced
cell proliferation
Both insulin and TPA stimulate proliferation of Hep3B
cells. To investigate the e¡ect of Rap1 on the mitogenesis of
these two agents, Hep3B and Hep3B/Rap1 cells were seeded
in 24-well plates. They were treated with various concentra-
tions of either insulin or TPA for 48 h after serum starvation.
As shown in Fig. 3A, insulin stimulated proliferation of
Hep3B cells in a dose-dependent manner, but the mitogenic
e¡ect was diminished in two Rap1 clones. Rap1-12 clone,
which expressed a higher level of rap1 mRNA than Rap1-3
clone, has more dramatic reduction in the mitogenic response.
The reduction of TPA-induced cell proliferation was also ob-
served in Rap1 transfectants, 20 ng/ml of TPA induced a 50%
increase in Hep3B cells after 48 h treatment, while in Rap1-3
clone, the mitogenic e¡ect was diminished to 10% (Fig. 3B).
4. Discussion
Loss of contact inhibition is a parameter of oncogene-in-
duced transformation in cultured cells, and this phenomenon
can be measured from the increase of saturation density. We
found that expression of Rap1 reduced the saturation density
of Hep3B/Rap1-3 and Rap1-12 by 40% compared to parental
Hep3B cells. This decrease provided evidence to support a
reversion-inductive activity of Rap1 in transformed cells. Fur-
thermore, expression of Rap1 completely suppressed the tu-
morigenicity of parental Hep3B cells. Caamano et al. have
shown that overexpression of rap1 gene partially suppresses
the tumorigenicity of a lung cancer cell line Calu-6 [32]. In
polyomavirus middle T antigen-transformed Rat-2 cells, Rap1
also induces reversion of transformation [30]. However, the
mechanism of this anti-transforming e¡ect remains unclear.
Constitutively activated MEK induces transformation of
NIH3T3 cells [35]. These observations have indicated that
activation of the Raf/MEK/ERKs pathway may be su⁄cient
to trigger transformation in certain cells. If signalings through
the ERK pathway were involved in maintaining the transfor-
mation state, then blockage of Ras/ERKs activation could be
useful in inhibiting the transformed phenotype. Chen et al.
have demonstrated that addition of cAMP or expression of
a mutant-activated GKs (Q227L) inhibited the tumorigenesis
of MCF-7 human breast cancer cells and showed that the
ERK signaling pathway may be involved in regulation of
transformed phenotypes [36]. An oncogenic e¡ect of Rap1b
has been reported in Swiss 3T3 cells, in which Rap1 increases
DNA synthesis and cAMP exerts a stimulatory e¡ect on cell
growth [33]. It is not surprising that overexpression of Rap1b
exhibits mitogenic and oncogenic phenomena in a cell line
where cAMP is known to be a positive regulator of cell
growth. Interestingly, the mitogenic action of Rap1b is only
revealed in the presence of other growth factors, i.e. insulin/
insulin-like growth factor 1, which activates the Ras/ERK
pathway. This synergistic behavior implies a collaboration
between Ras-dependent and cAMP-dependent signaling
events. It would be interesting to verify the activation of
ERKs in the Rap1b-expressing cells. In this paper, we showed
for the ¢rst time that Rap1 completely abolishes tumorigenic-
ity of human hepatoma cells in nude mice and the concom-
itance between tumorigenic inhibition and ERK activation. It
has long been known that cAMP inhibits cell proliferation in
certain cells, while stimulating in others. Rap1 is activated by
signals that raise the intracellular level of cAMP [37,38], sug-
gesting that Rap1 may be intimately linked with some of the
cAMP biological e¡ects. It is very likely that introduction of
Rap1 may amplify the ‘basal’ cAMP signal in Hep3B cells,
which may inhibit ERK activation and cause the reversion of
transformed phenotype.
The physiological role of Rap1 in regulating intracellular
signaling appears to be enigmatic and can be either positive or
negative dependent upon the cell context. Expression of a
constitutively active Rap1 (RapV12) inhibited the ERK acti-
vation induced by LPA and EGF in Rat-1 ¢broblasts [7].
These results implied that Rap1 activation serves to modulate
Ras signaling. However, Zwartkruis et al. have shown that
EGF activated Rap1 in Rat-1, and this activation did not
a¡ect ERK-2 activation in Rat-1 cells [16]. These data sug-
gested that Rap1 can be activated by growth factors, and this
activation is not necessarily related to the Ras/Raf/MEK/
ERK pathway. These paradoxical data may be explained by
the possibility that activation of endogenous Rap1 does not
interfere with growth factors-induced Raf-1/MEK/ERK acti-
vation, because it is unlikely that growth factors activate
Rap1 to repress Ras e¡ector signaling. However, overexpres-
sion of active Rap1 may interfere in Ras signaling, presum-
ably by trapping Raf-1 in an inactive complex. Nevertheless,
Okada et al. have shown that insulin induced a time-depen-
dent decrease in the amount of GTP bound to endogenous
Rap1 in CHO cells. This inactivation of Rap1 was associated
with an insulin-stimulated decrease in the amount of Rap1-
Raf-1 complex. Concomitant with the inactivation of Rap1
and decrease in Rap-Raf-1 binding, a rapid insulin-stimulated
dissociation of the CrkII-C3G complex was observed. Activa-
tion of insulin receptor kinase may induce the tyrosine phos-
phorylation of CrkII-C3G complex. The uncoupling of CrkII
from C3G allowed conversion of Rap1 from the active GTP-
bound conformational state to the inactive GDP form. The
inactivation of Rap1 released the bound Raf-1, which can
then associate with GTP-bound Ras, resulting in the activa-
tion of the Raf-1/MEK/ERK cascade [27]. These results sug-
gest that endogenous Rap1 antagonizes Ras function by pre-
venting Raf-1 coupling with Ras, and this antagonizing e¡ect
can be regulated by insulin. In our study, we showed that
expression of a wild-type Rap1 inhibited insulin-induced
ERK activation and cell proliferation. Inhibition of the Ras/
Raf/MEK/ERK pathway blocked insulin-induced cell prolif-
eration in Hep3B cells (Yea-Lih Lin, unpublished data). This
phenomenon implies that wild-type Rap1 can function as an
antagonist to Ras in Hep3B cells.
With respect to TPA, the involvement of Rap1 in ERK
activation or inactivation remains unclear. In Rat-1 ¢bro-
blasts, TPA activates Rap1 and this activation does not con-
tribute or a¡ect ERK-2 activation, while expression of active
Rap1 blocks the activation of c-fos promoter by K-Ras or
TPA, but not by Raf-1 in transient transfected NIH3T3 cells
[39]. Here, we show for the ¢rst time that expression of Rap1
inhibits TPA-induced ERK activation. We have found that
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TPA stimulates MEK/ERKs and cell proliferation through a
Ras-dependent pathway. These results further suggest that
Rap1 interferes with Ras e¡ects in terms of ERKs activation
and cell proliferation in Hep3B cells.
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